Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA®…
Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy Bolsters Presence in Neuroscience Expected to be Accretive…